Fennec Pharmaceuticals Inc. (TSE:FRX) Forecasted to Post FY2025 Earnings of $0.97 Per Share

Fennec Pharmaceuticals Inc. (TSE:FRX) – Research analysts at Capital One Financial raised their FY2025 earnings per share (EPS) estimates for shares of Fennec Pharmaceuticals in a note issued to investors on Thursday, May 2nd. Capital One Financial analyst N. Quibria now expects that the biopharmaceutical company will earn $0.97 per share for the year, up from their previous forecast of $0.96. The consensus estimate for Fennec Pharmaceuticals’ current full-year earnings is $0.42 per share. Capital One Financial also issued estimates for Fennec Pharmaceuticals’ FY2026 earnings at $1.63 EPS and FY2028 earnings at $4.63 EPS.

Fennec Pharmaceuticals (TSE:FRX) last posted its quarterly earnings data on Thursday, March 21st. The biopharmaceutical company reported C($0.14) earnings per share for the quarter, missing the consensus estimate of C$0.02 by C($0.16). The business had revenue of C$13.25 million during the quarter, compared to the consensus estimate of C$12.88 million. Fennec Pharmaceuticals had a negative net margin of 75.50% and a negative return on equity of 1,005.59%.

Fennec Pharmaceuticals Price Performance

TSE:FRX opened at C$12.50 on Monday. The company has a debt-to-equity ratio of 881.09, a current ratio of 3.56 and a quick ratio of 10.17. The stock has a market cap of C$338.75 million, a P/E ratio of -15.24 and a beta of 0.40. The company has a fifty day moving average price of C$13.57 and a 200 day moving average price of C$12.94. Fennec Pharmaceuticals has a one year low of C$9.27 and a one year high of C$15.43.

Insider Activity

In related news, Senior Officer Adrian J. Haigh bought 22,222 shares of Fennec Pharmaceuticals stock in a transaction that occurred on Monday, April 15th. The stock was acquired at an average price of C$2.31 per share, for a total transaction of C$51,332.82. In other news, Senior Officer Robert Christopher Andrade sold 13,975 shares of the firm’s stock in a transaction dated Tuesday, March 26th. The shares were sold at an average price of C$10.90, for a total transaction of C$152,345.67. Also, Senior Officer Adrian J. Haigh bought 22,222 shares of the stock in a transaction that occurred on Monday, April 15th. The stock was acquired at an average cost of C$2.31 per share, for a total transaction of C$51,332.82. Over the last 90 days, insiders sold 39,112 shares of company stock valued at $390,926. Insiders own 14.60% of the company’s stock.

About Fennec Pharmaceuticals

Fennec Pharmaceuticals Inc operates as a biopharmaceutical company in the United States. The company's product candidate includes PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients. It sells its products through regional pediatric oncology specialists and medical science liaisons.